Here are a few brief analogies for Hyperfine:

• Square for portable MRI machines
• Abbott for point-of-care MRI diagnostics

• Swoop Portable MR Imaging System: This system provides point-of-care medical imaging through a combination of hardware and software services.

Koninklijke Philips N.V. (Symbol: PHG)

Amazon.com, Inc. (Symbol: AMZN)

Maria Sainz, President and Chief Executive Officer

Maria Sainz possesses over 30 years of experience in commercial and leadership roles within the medical technology industry. Prior to joining Hyperfine, she served as President and CEO of AEGEA Medical, a women's health technology company acquired by CooperSurgical in 2021. She also held the position of President and CEO at Cardiokinetix and Concentric Medical, Inc., which was acquired by Stryker in 2011. Sainz also serves on the Boards of Directors for ShockWave Medical, Inc., Avanos Medical, Inc., and Atrion Corporation.

Brett Hale, Chief Administrative Officer and Chief Financial Officer

Brett Hale brings over 25 years of financial and administrative leadership experience, with more than two decades in the medical technology sector. His previous roles include CFO at Bigfoot Biomedical, Inc., Cardiokinetix Inc., and Concentric Medical, Inc. He oversaw Concentric Medical, Inc. through its acquisition by Stryker Corp. in 2011. Hale also held various financial positions at Emphasys Medical and Guidant Corporation and was an Assurance Manager at PricewaterhouseCoopers.

Tom Teisseyre, PhD, Chief Operating Officer

Tom Teisseyre, PhD, was promoted to Chief Operating Officer in July 2023, having previously served as Hyperfine's Chief Product Officer since June 2021. His extensive background includes serving as head of Surgical and Implantable Devices and being a founding member of Verily Life Science, formerly Google Life Sciences. He has held senior positions at Google, Abbott Medical Optics, Proximie, and OptiMedica, demonstrating expertise in medical devices, medtech, and imaging. Dr. Teisseyre holds patents and has published works in medical imaging, medical image processing, intraoperative imaging, surgical technology, and surgical workflow optimization.

Rob Fasciano, PhD, Chief Regulatory and Quality Officer

Rob Fasciano, PhD, has over 25 years of experience in the medical device and diagnostic industry. He has held leadership roles in R&D, Quality, and Regulatory Affairs at companies such as Abiomed, Johnson & Johnson, Orchestra BioMed, and Impulse Dynamics.

Edmond Knopp, MD, Chief Medical Officer

Edmond Knopp, MD, serves as the Chief Medical Officer at Hyperfine.

Here are the key risks to Hyperfine (HYPR):

1. Significant Cash Burn, Unprofitability, and Dilution Risk: Hyperfine is currently unprofitable and is not projected to achieve profitability within the next three years. The company has a substantial cash burn rate; for example, in the past year, it burned through $36 million against a market capitalization of $48 million, which is 76% of its market value. This significant cash consumption results in a short cash runway, estimated at approximately 11 months as of March 2025, necessitating a reduction in cash burn or replenishment of cash reserves. This heavy cash burn makes the company reliant on capital markets for funding, posing a significant risk of extreme shareholder dilution. Furthermore, Hyperfine's Altman Z-Score of -2.1 indicates it is in a distress zone, suggesting a potential risk of bankruptcy within the next two years.
2. Market Acceptance and Intense Competition: Hyperfine faces substantial challenges in achieving widespread market acceptance for its Swoop Portable MR imaging system. Sustained growth is vulnerable to delays, competitive innovation, and setbacks in technological integration and payer acceptance. The company operates in a highly competitive medical device industry against multi-billion dollar competitors like Siemens Healthineers and GE HealthCare, which possess dominant market share, massive scale, and established profitability. Hyperfine's ability to prove the clinical utility and diagnostic accuracy of its low-field system over existing imaging alternatives is crucial for broad adoption, requiring extensive clinical data, publications, and robust sales and marketing efforts where it is at a severe disadvantage.
3. Regulatory Hurdles and Technological Integration/Development Risks: As a medical device company, Hyperfine's success is dependent on its ability to obtain and maintain regulatory clearances and approvals for its products. The company's growth expectations can be impacted by regulatory headwinds and delays in technological integration. Furthermore, the ongoing need for product development and commercialization activities, including investments in research and development, and the ability to identify and acquire additional technology, represent continuous risks in a rapidly evolving healthcare industry.

The addressable markets for Hyperfine, Inc.'s main product, the Swoop Portable MR imaging system, encompass the global portable MRI market and the broader global point-of-care medical imaging market.

Global Portable MRI Market

The global portable MRI market was valued at approximately USD 2.98 billion in 2024 and is projected to reach around USD 5.59 billion by 2034, exhibiting a compound annual growth rate (CAGR) of about 6.49% from 2025 to 2034. Other estimates suggest the global portable MRI market was valued at USD 1.25 billion in 2024 and is projected to reach approximately USD 3.02 billion by 2030, with a CAGR of 15.8%. Another report indicates a market size of USD 4.34 billion in 2025, expected to grow to approximately USD 7.35 billion by 2035, with a CAGR of 5.41% from 2026 to 2035.

U.S. Portable MRI Market

The U.S. portable MRI market, specifically for mobile MRI services, was estimated at USD 3.67 billion in 2024 and is projected to grow at a CAGR of 3.52% from 2025 to 2030. Another projection shows the U.S. mobile MRI services market size at USD 3.99 billion in 2025, estimated to reach around USD 5.67 billion by 2035, growing at a CAGR of 3.58% from 2026 to 2035.

Global Point-of-Care Medical Imaging Market

The global point-of-care medical imaging market was valued at USD 1.21 billion in 2022 and is anticipated to increase at a CAGR of 4.3% from 2023 to 2030. More recently, the global point-of-care medical imaging market size was calculated at USD 1.39 billion in 2025 and is predicted to increase to approximately USD 2.16 billion by 2035, expanding at a CAGR of 4.51% from 2026 to 2035.

Hyperfine (Nasdaq: HYPR) is poised for future revenue growth over the next two to three years, driven by several strategic initiatives and market expansions:

• Commercialization of Next-Generation Swoop System and Optive AI Software: Hyperfine has launched its next-generation Swoop system, powered by its Optive AI™ software, which is expected to drive broad adoption across various healthcare settings. This new software has also been rolled out to the existing installed base of Swoop scanners in the United States, Canada, the United Kingdom, Australia, and New Zealand, providing a significant upgrade and potential for increased utilization.
• Expansion into the Neurology Office Market: The company has initiated a full-scale commercial launch of its Swoop system within the neurology office setting. This expansion aims to unlock new revenue opportunities by addressing an unmet need in this specific market segment.
• International Market Penetration: Hyperfine is actively pursuing global expansion for its Swoop system. The receipt of CE Mark and UKCA Mark approvals for its Optive AI™ software facilitates its commercial rollout in key international markets, contributing to overall revenue growth.
• Growing Clinical Adoption and New Use Cases: Increased clinical adoption and the demonstration of new use cases, such as enhanced stroke detection capabilities, position the Swoop system for outsized revenue growth. This addresses the unmet need for point-of-care medical imaging and is supported by the publication of clinical data.

Share Issuance

• Hyperfine issued shares in a registered direct offering on February 11, 2025, selling 4,511,278 shares of Class A common stock and warrants, resulting in gross proceeds of approximately $6.0 million.
• The proceeds from the February 2025 offering are intended for working capital and general corporate purposes, including commercial, manufacturing, and research and development activities.
• The number of shares outstanding for Hyperfine has increased from 0.004 billion in Q4 2021 to 0.079 billion in Q3 2025, indicating shareholder dilution over this period.

Inbound Investments

• Hyperfine reported preliminary, unaudited net financing proceeds of approximately $19.3 million for the fourth quarter of 2025 and approximately $27.3 million for the full year ended December 31, 2025.

Capital Expenditures

• Capital expenditures in Q3 2025 totaled $0.13 million, representing a 75% decrease from the prior quarter.
• In the fiscal year 2025, capital expenditures consumed most of the company's operating cash flow, contributing to a -$39.1 million free cash flow, reflecting heavy capital investment.
• The capital expenditures fund long-term assets and infrastructure.